These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 20421530)

  • 1. Statin use and the risk of prostate-specific antigen recurrence after radiation therapy with or without hormone therapy for prostate cancer.
    D'Amico AV
    J Clin Oncol; 2010 Jun; 28(16):2651-2. PubMed ID: 20421530
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy.
    Stone NN; Stone MM; Rosenstein BS; Unger P; Stock RG
    J Urol; 2011 Feb; 185(2):495-500. PubMed ID: 21167528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
    Beyer DC; McKeough T; Thomas T
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
    Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M
    Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy.
    Kollmeier MA; Katz MS; Mak K; Yamada Y; Feder DJ; Zhang Z; Jia X; Shi W; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):713-8. PubMed ID: 20452139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
    Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Salvage radiotherapy in rising PSA after radical prostatectomy].
    Carrie C; Pommier P
    Cancer Radiother; 2007 Nov; 11(6-7):370-2. PubMed ID: 17869564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer.
    Soto DE; Daignault S; Sandler HM; Ray ME
    Urology; 2009 Jan; 73(1):158-62. PubMed ID: 18722651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31.
    Souhami L; Bae K; Pilepich M; Sandler H
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1301-6. PubMed ID: 20356687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matched-pair analysis of prostate cancer patients with a high risk of positive pelvic lymph nodes treated with and without pelvic RT and high-dose radiation using high dose rate brachytherapy.
    Vargas CE; Demanes J; Boike TP; Barnaba MC; Skoolisariyaporn P; Schour L; Gustafson GS; Gonzalez J; Martinez AA
    Am J Clin Oncol; 2006 Oct; 29(5):451-7. PubMed ID: 17023778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
    Lee HK; Adams MT; Motta J
    Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer.
    Krauss D; Kestin L; Ye H; Brabbins D; Ghilezan M; Gustafson G; Vicini F; Martinez A
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1064-71. PubMed ID: 20584576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age.
    Terakedis BE; Rossi PJ; Liauw SL; Johnstone PA; Jani AB
    Am J Clin Oncol; 2010 Dec; 33(6):619-23. PubMed ID: 20051808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.
    Moul JW; Zlotta AR
    BJU Int; 2005 Feb; 95(3):285-90. PubMed ID: 15679779
    [No Abstract]   [Full Text] [Related]  

  • 20. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
    D'Amico AV; Saegaert T; Chen MH; Renshaw AA; George D; Oh W; Kantoff PW
    Cancer; 2002 Jul; 95(2):275-80. PubMed ID: 12124826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.